Welcome to our dedicated page for Acutus Medical news (Ticker: AFIB), a resource for investors and traders seeking the latest updates and insights on Acutus Medical stock.
Acutus Medical, Inc. reports developments tied to its left-heart access product business and its transition away from electrophysiology mapping and ablation. The company focuses on production of left-heart access products under a distribution agreement with Medtronic, with recurring updates on continuing-operations revenue, manufacturing volume, gross margin, operating expenses, and gains related to business sales.
News also covers corporate restructuring, strategic realignment of resources, discontinued legacy mapping and ablation operations, and changes in financial guidance practices.
Acutus Medical, dedicated to arrhythmia management, announced its management's participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. The company focuses on enhancing cardiac arrhythmia diagnosis and treatment through innovative electrophysiology technologies. Established in 2011 and based in Carlsbad, California, Acutus aims to provide comprehensive catheter-based solutions for arrhythmia treatment globally.
Acutus Medical, Inc. (Nasdaq: AFIB) will release its third-quarter 2020 financial results on November 12, 2020, after market close. The company will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and recent developments. Interested parties can listen to the call by dialing (833) 570-1131 or (914) 987-7078 and using conference ID: 6990208. A live webinar will also be available on Acutus' investor relations website, with a replay accessible shortly after the call concludes.
Acutus Medical (AFIB) received FDA 510(k) clearance for its second-generation AcQMap® 3D imaging and mapping catheter. This innovative device improves handling and deliverability, featuring 48 ultrasound transducers and 48 engineered electrodes for enhanced cardiac mapping. Key benefits include faster anatomy reconstruction, procedural efficiency, and a reusable cable that can save healthcare costs. The AcQMap System allows for efficient mapping of various atrial arrhythmias, supporting rapid diagnosis and treatment.
Acutus Medical reported Q2 2020 revenue of $1.1 million, a 54% increase year-over-year, but a decrease from $1.6 million in Q1. The company noted a net loss of $23.2 million, with a net loss per share of $32.24. Strong console placements led to a growing installed base of 38 AcQMap consoles, including 21 2nd generation machines. Despite challenges from COVID-19 impacting procedures, the company is optimistic about future growth. Cash reserves stand at $29.5 million as of June 30, 2020. Due to pandemic uncertainties, no financial guidance for the remainder of 2020 was provided.
Acutus Medical (Nasdaq: AFIB) will release its Q2 2020 financial results on September 17, 2020, post-market. A conference call and webcast are scheduled for 1:30 p.m. PT (4:30 p.m. ET) to discuss these results and recent highlights. Interested parties can join the call at (833) 570-1131 (domestic) or (914) 987-7078 (international) using conference ID: 9767216. The event will also be available for replay on the company's website for two weeks.
Acutus Medical, Inc. (Nasdaq: AFIB) successfully closed its initial public offering of 10,147,058 shares of common stock on August 10, 2020, including the full exercise of underwriters’ options for an additional 1,323,529 shares. The offering price was $18.00 per share, generating approximately $182.6 million in gross proceeds. The shares began trading on the Nasdaq on August 6, 2020. J.P. Morgan and BofA Securities acted as joint book-running managers for the offering.
Acutus Medical, Inc. (NASDAQ: AFIB) announced its initial public offering (IPO) on August 5, 2020, pricing 8,823,529 shares at $18.00 each. The offering is projected to raise approximately $158.8 million before expenses, with trading starting on August 6, 2020. The offering's close is anticipated on August 10, 2020, dependent on customary conditions. The underwriters have a 30-day option for an additional 1,323,529 shares. J.P. Morgan and BofA Securities act as joint book-running managers, while registration statements were filed with the SEC effective the same day.